Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases

Zhi Guo1,2, Jie Zhu2, Jun Wang3

  • 1Department of Hematology, The Sixth Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China.

Frontiers in Medicine
|April 16, 2025
PubMed

Intravenous immunoglobulin (IVIG), first developed for the treatment of patients with antibody deficiencies, is now widely used in clinical practice, especially in hematological and immune system diseases, and its application in hematological oncology chemotherapy, cellular immunotherapy and hematopoietic stem cell transplantation (HSCT) is becoming more and more common. The Chinese Collaborative Group for Infection Immunology and Microecology Research Translation Collaborative Group organized relevant experts to discuss and propose the "Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases," which was formulated based on the progress of research on the application of IVIG in blood diseases, and provides a basis for the standardization of the use of IVIG in hematologic disorders.